Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). What makes MS particularly devastating is its progressive nature.Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath.The case for Lucid-MS is grounded in more than a decade of rigorous science.Quantum BioPharma's path to phase 2 has been methodical and deliberate. Click here to view the custom infographic of the Quantum BioPharma editorial. A Disease That Steals People’s Movement and Momentum Multiple sclerosis is a chronic, inflammatory disease of the central nervous system. The immune system turns against the brain and spinal cord, attacking myelin, the protective sheath that surrounds nerve fibers and allows electrical signals to travel efficiently. As myelin degrades, those signals slow, stall or stop entirely. The result is an unpredictable cascade of symptoms, including tingling sensations, vision problems, mobility issues, cognitive impairment, and eventually the progressive loss of physical control. The disease does not discriminate by age. The average global age of diagnosis is 32, and rou...

View stock analysis, news, and events for Quantum Biopharma Ltd. Subordinate Voting Shares Class B